Hansa Biopharma AB (publ)

OM:HNSA Stock Report

Market Cap: kr1.6b

Hansa Biopharma Management

Management criteria checks 2/4

Hansa Biopharma's CEO is Søren Tulstrup, appointed in Mar 2018, has a tenure of 6.08 years. total yearly compensation is SEK27.51M, comprised of 30.7% salary and 69.3% bonuses, including company stock and options. directly owns 0.057% of the company’s shares, worth SEK929.80K. The average tenure of the management team and the board of directors is 4 years and 4.9 years respectively.

Key information

Søren Tulstrup

Chief executive officer

kr27.5m

Total compensation

CEO salary percentage30.7%
CEO tenure6.1yrs
CEO ownership0.06%
Management average tenure4yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Apr 05
Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Feb 07
Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Dec 28
Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Oct 13
Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Sep 22
Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

May 31
Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Apr 03
Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Feb 06
Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

Feb 01
Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

CEO Compensation Analysis

How has Søren Tulstrup's remuneration changed compared to Hansa Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023kr28mkr8m

-kr832m

Sep 30 2023n/an/a

-kr856m

Jun 30 2023n/an/a

-kr759m

Mar 31 2023n/an/a

-kr678m

Dec 31 2022kr26mkr8m

-kr611m

Sep 30 2022n/an/a

-kr626m

Jun 30 2022n/an/a

-kr620m

Mar 31 2022n/an/a

-kr583m

Dec 31 2021kr26mkr7m

-kr548m

Sep 30 2021n/an/a

-kr491m

Jun 30 2021n/an/a

-kr465m

Mar 31 2021n/an/a

-kr431m

Dec 31 2020kr21mkr6m

-kr421m

Sep 30 2020n/an/a

-kr426m

Jun 30 2020n/an/a

-kr398m

Mar 31 2020n/an/a

-kr381m

Dec 31 2019kr11mkr5m

-kr360m

Sep 30 2019n/an/a

-kr330m

Jun 30 2019n/an/a

-kr298m

Mar 31 2019n/an/a

-kr274m

Dec 31 2018kr8mkr4m

-kr248m

Compensation vs Market: Søren's total compensation ($USD2.51M) is above average for companies of similar size in the Swedish market ($USD231.08K).

Compensation vs Earnings: Søren's compensation has increased whilst the company is unprofitable.

CEO

Søren Tulstrup (58 yo)

6.1yrs

Tenure

kr27,505,000

Compensation

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...

Leadership Team

NamePositionTenureCompensationOwnership
Søren Tulstrup
President & CEO6.1yrskr27.51m0.057%
SEK 929.8k
C. Ballantyne
Chief Financial Officerless than a yearno datano data
Christian Kjellman
Senior VP & COO4.3yrsno datano data
Hitto Kaufmann
Chief Scientific Officerless than a yearno datano data
Eva-Maria Joed
Vice President of Finance & Administration4.9yrsno datano data
Klaus Sindahl
VP & Head of Investor Relationsno datano datano data
Anne Lanner
Senior VP & Chief Human Resources Officer5.3yrsno datano data
Emanuel Björne
VP & Head of Business Developmentno datano datano data
Lena Winstedt
Head of Scienceno datano datano data
Vincenza Nigro
VP & Head of Medical Affairsno datano datano data
Achim Kaufhold
Senior VP & Chief Medical Officer3.8yrsno datano data
Magnus Korsgren
VP & Head of Research and Development3yrsno datano data

4.0yrs

Average Tenure

54yo

Average Age

Experienced Management: HNSA's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Anders Pedersen
Independent Director5.9yrskr413.00k0.0045%
SEK 73.7k
Mats Blom
Independent Director4.9yrskr493.00k0.0018%
SEK 29.5k
Peter Nicklin
Independent Chairman of the Board1.8yrskr1.14m0.045%
SEK 722.3k
Eva Nilsagard
Independent Director4.9yrskr591.00k0.0054%
SEK 88.4k
Hilary Malone
Independent Director2.9yrskr725.00kno data
Andreas Eggert
Independent Director5.9yrskr595.00k0.010%
SEK 162.1k
Gunnar Tufveson
Chairman of European Medical Advisory Board in Transplantationno datano datano data
Kathryn Wood
Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantationno datano datano data
Christophe Legendre
Member of European Medical Advisory Board in Transplantationno datano datano data
Stanley Jordan
Chairman of US Medical Advisory Board in Transplantationno datano datano data
Robert Montgomery
Member of US Medical Advisory Board in Transplantationno datano datano data

4.9yrs

Average Tenure

58.5yo

Average Age

Experienced Board: HNSA's board of directors are considered experienced (4.9 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.